---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-004015"
form_type: "8-K"
ticker: "CBIO"
cik: "0001253689"
company_name: "CRESCENT BIOPHARMA, INC."
filed_at: "2024-03-27T23:59:59+00:00"
generated_at: "2026-06-04T07:00:04.668476+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# GlycoMimetics reports Q4/FY2023 cash $41.8M; Phase 3 uproleselan topline in Q2 2024

## Summary
- Cash and equivalents $41.8M at Dec 31, 2023, down from $47.9M at Dec 31, 2022.
- Phase 3 uproleselan topline results expected Q2 2024; NDA submission by end-2024 if positive.
- Phase 1a GMI-1687 met primary and secondary endpoints; research agreement with ASH RC for SCD.
- R&D expenses FY2023 $20.1M (down from $28.4M); G&A $19.2M (flat vs $19.1M).

## SEC filing metadata
- accession: 0001558370-24-004015
- form_type: 8-K
- ticker: CBIO
- cik: 0001253689
- company_name: CRESCENT BIOPHARMA, INC.
- filed_at: 2024-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1253689/000155837024004015/0001558370-24-004015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1253689/000155837024004015/glyc-20240327x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-004015
- JSON: https://secwatch.observer/filing/0001558370-24-004015.json
- Plain text: https://secwatch.observer/filing/0001558370-24-004015.txt

## Key facts
- Earnings Releases
  CRESCENT BIOPHARMA, INC. reported financial results for the quarter and year ended December 31, 2023.
  - Period: the quarter and year ended December 31, 2023
  - Result: reported results
  source text: On March 27, 2024, GlycoMimetics, Inc. (the “ Company ”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837024004015/0001558370-24-004015-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.